News from twi pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 17, 2015, 05:37 ET

TWi Biotechnology Inc. Announces Development and Commercialization Agreement and Collaboration with Castle Creek Pharmaceuticals, LLC

TWi Pharmaceuticals, Inc. (4180.TT) today announced that its subsidiary, TWi Biotechnology, Inc. (TWiB), and Castle Creek Pharmaceuticals, LLC...

Dec 15, 2015, 23:48 ET

TWi Pharmaceuticals, Inc. Receives Favorable Decision from the U.S. Court of Appeals for the Federal Circuit Regarding TWi's Generic Version of MEGACE ES(R) 625mg/5ml

TWi Pharmaceuticals, Inc. ("TWi") (Stock Ticker: 4180.TT) today announced that it has received a favorable decision from the U.S. Court...

Nov 12, 2015, 20:38 ET

TWi Pharmaceuticals Announces Plan to Reorganize its US Operation and Appoints Rick Pallokat as Executive Vice President Commercial Operations to Grow its US business

TWi Pharmaceuticals Inc. (4180.TT) ("TWi") today announced that its board has appointed Mr. Rick Pallokat as the Executive Vice President of its...

Oct 27, 2015, 06:26 ET

TWi Biotechnology Receives Notice of Patent Allowance in Korea for its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes

TWi Biotechnology, Inc., today announced that it has received Notice of Allowance for AC-201, TWi Biotechnology's lead drug candidate, from the...

Sep 16, 2015, 22:52 ET

TWi Pharmaceuticals Issues GDR and Raised NT$ 2.83 Billion

TWi Pharmaceuticals, Inc. ("TWi") (Stock Ticker: 4180.TT) today announced that it has priced and issued 14.40 million units of GDR (Global...

Aug 30, 2015, 05:46 ET
Aug 13, 2015, 23:01 ET

TWi Pharmaceuticals Announces 2Q 2015 Financial Results and EPS for 2Q of NT$0.69

TWi Pharmaceuticals, Inc. (4180.TW) today announced that its board had approved 2015 first half financial results; the cumulative 1st half sales...

Aug 03, 2015, 03:43 ET

TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in Europe and Russia

TWi Biotechnology, Inc., today announced that it has received Notices of Allowance for AC-201, TWi Biotechnology's lead drug candidate, from the...

Jul 28, 2015, 21:38 ET

TWi Pharmaceuticals Launches Generic MEGACE ES(R) After Favorable Decision In Patent Suit

TWi Pharmaceuticals, Inc. today announced that it launched its generic version of Par Pharmaceutical's MEGACE ES® (megestrol acetate oral...

Jun 03, 2015, 02:44 ET

TWi Pharmaceuticals Receives US FDA Final Approval on Generic Guanfacine HCl ER Tablet

TWi Pharmaceuticals, Inc. ("TWi") (stock ticker: 4180.TT) today announced that it has received final approval from the United States Food and Drug...

May 14, 2015, 06:14 ET

TWi Pharmaceuticals Announced the Promotion of R&D EVP Jianbo Xie as COO

TWi Pharmaceuticals, Inc. ("TWi") (Stock Ticker:4180.TT) announced that its R&D Executive Vice President (EVP) Mr. Jianbo...

Apr 27, 2015, 05:05 ET

TWi Announces Settlement with Takeda on Dexilant(R) Litigation

TWi Pharmaceuticals, Inc. ("TWi") today announced that it has entered into a Settlement Agreement with Takeda Pharmaceutical Company Limited,...

Apr 17, 2015, 06:22 ET

TWi Pharmaceuticals USA Announces the Receipt of State Sales Licenses from All 50 States in the U.S.

TWi Pharmaceuticals, Inc. ("TWi", Stock Ticker:4180.TT) today announced that its fully-owned subsidiary, TWi Pharmaceuticals USA, has obtained...

Mar 17, 2015, 04:51 ET
TWi products in the US warehouse

TWi Pharmaceuticals Announces The First Shipment of its Generic Product in the U.S. Market.

TWi Pharmaceuticals, Inc. ("TWi") (4180.TW) announced today that its wholly-owned subsidiary, TWi Pharmaceuticals USA, shipped the first generic...

Mar 10, 2015, 07:05 ET

TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan

TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received the designation of Rare Disease...

Mar 05, 2015, 06:26 ET

TWi Pharmaceuticals Announces that Its Board Has Appointed Ms. Tina Guilder as the President & CEO and Ms. Eva Ho as CFO to Enhance the Strategic Move to Commercialize Its Products in the U.S. Market.

TWi Pharmaceuticals, Inc. ("TWi") today announced that its Board of Directors has unanimously approved to appoint Ms. Tina Guilder as its new...

Feb 23, 2015, 20:59 ET

TWi Pharmaceuticals Announces That It Will Sell Its Products in the U.S. Market, Originally Planned to Be Sold by Teva, Through Its Wholly-Owned Subsidiary, TWi Pharmaceuticals USA

TWi Pharmaceuticals, Inc. ("TWi") (4180:Taiwan) today announced that TWi and Teva Pharmaceuticals ("Teva") have reached an agreement that will...

Dec 22, 2014, 03:35 ET

TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China

TWi Biotechnology, Inc., today announced that it has received Notice of Allowance for AC-201, TWi Biotechnology's lead drug candidate, from The...

Dec 12, 2014, 04:22 ET

TWi Biotechnology Receives Approval of Protocol for Its Drug AC-201 Controlled-Release Tablet, Phase II Clinical Trial in Both the United States and Taiwan

 TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received US FDA and Taiwan FDA...

Oct 30, 2014, 04:15 ET

TWi Pharmaceuticals Receives US FDA Approval on Generic Donepezil Hydrochloride Tablets USP, 23 mg, its fifth ANDA from US FDA

 TWi Pharmaceuticals, Inc. today announced that it has received final approval from the United States Food and Drug Administration (FDA) on its...